Epstein-Barr virus (EBV) is involved in the pathogenesis of several B cell lymphoproliferations, but the precise contribution it makes to the aetiology of each remains unclear. In vitro, the virus has potent growth transforming activity and efficiently induces the continuous proliferation of normal human B cells. A comparison of EBVinfected primary B cells with an isogenic population induced to proliferate by CD40-ligand (CD40L) and IL4 has revealed that EBV can override -by a novel mechanism -the p53/pRb-mediated G1 checkpoint activated in normal B cells by a genotoxic stress. In cells responding to cisplatin, although p53 is stabilized and activated, EBV latent gene expression appears to inhibit the accumulation of newly synthesized p21 WAF1/CIP1 and the downregulation of cyclin D2 that occur in the normal cells. Consequently, in the EBV-infected cells, CDK2 remains active, hyperphosphorylation of pRb is maintained and the replication of damaged DNA can occur. Under conditions of severe genomic stress, this absence of p21
Introduction
When Epstein-Barr virus (EBV) induces the continuous proliferation of human B cells it is widely assumed that expression of EBV latency-associated genes mimics the physiological activation of B cells by specific antigen binding and cognate T-cell help. This is in contrast to the small DNA tumour viruses that induce cells to bypass cell cycle checkpoints (Bornkamm and Hammerschmidt, 2001; Rickinson, 2001) . The lymphoblastoid cell lines (LCLs) that are generated by infecting resting human B cells in vitro have a phenotype resembling activated B-blasts. These growth-transformed cells express only nine latency-associated EBV proteins (this is known as the proliferation programme or latency III). There are six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and Leader Protein (EBNALP)) and three latent membrane proteins (LMP1, LMP2A and LMP2B). Additionally, several viral RNA species of uncertain function are expressed. Together the latent proteins activate quiescent B cells into the cell cycle, induce continuous proliferation and maintain the viral genome as extrachromosomal episomes (reviewed in Bornkamm and Hammerschmidt, 2001) . In vivo this ability of the virus to drive B-cell proliferation is transient but essential because these LCL-like cells retain the capacity to undergo differentiation in lymphoid tissue and thus permit latent viral genomes to enter the long-lived memory B-cell pool, the site of long-term persistence (Thorley-Lawson and Babcock, 1999; Thorley-Lawson, 2001 ). Although EBV is carried for life as a nonpathogenic infection by more than 90% of the adult population, it is associated with a number of diseases. In addition to causing the self-limiting and relatively benign lymphoproliferative disorder infectious mononucleosis (IM), EBV is associated with several B cell tumours, including posttransplant lymphoproliferative disease (PTLD), endemic Burkitt's lymphoma (BL) and Hodgkin's disease (HD). However, the precise contribution that EBV makes to the pathogenesis of these various B cell neoplasias is not known (Rickinson, 2001; Kelly et al., 2002; Speck, 2002; Timms et al., 2003) .
There is some evidence that overexpressed individual EBV latent proteins, such as EBNA3C, can disrupt cell cycle regulation (Parker et al., 2000) and that latent EBV gene expression in tumour-derived B cells can alter the cells' responsiveness to genotoxic drugs (Wade and Allday, 2000) . However, a detailed comparison of normal B cells infected by EBV with an isogenic population stimulated by physiological agents has not been described. In order to determine whether latent EBV disrupts cell cycle checkpoint regulation, here we compare the effect of the genotoxic drug cisplatin on proliferating B-blasts generated from a single population by either infection with EBV or exposure to CD40-ligand and IL4. This has revealed significant differences that are consistent with EBV disrupting the G1 checkpoint linked to the p53-pRb axis targeted by the small DNA tumour viruses. However, EBV acts downstream of the tumour suppressor p53 and appears to prevent the inactivation of cyclin-dependent kinase (CDK) 2 by p21 WAF1/CIP1 perhaps by targeting the latter for degradation by the proteasome system.
Results
When it was first reported that human B cells could be grown in culture for prolonged periods if they were stimulated through CD40 in the presence of IL4, it was suggested that proliferating cells could be maintained for many weeks and perhaps months (Banchereau et al., 1991) . Subsequently it was reported that, although IL10 could induce CD40-activated B cells to differentiate into plasma cells, IL4 did not have this effect (Rousset et al., 1995) . Using this system with murine fibroblasts expressing CD40L (CD154) in combination with recombinant IL4 (Figure 1a) , we have consistently found that CD19-positive peripheral human B cells actively proliferate in culture for only 3-4 weeks before arresting and showing signs of terminal differentiation (manuscript in preparation). Our results are consistent with those of another group that recently reported similar limited proliferation of tonsillar B cells treated with these mitogens, after which it was assumed that they had undergone premature senescence (Shvarts et al., 2002) . Since we were interested in comparing EBV-infected cells with normal B cells at the same stage of differentiation and with a similar rate of proliferation, all of the experiments using primary B cells described here were performed on cells that had been in culture for only 7-10 days. At this time, the mitogen-driven cells were largely indistinguishable from the EBV-driven cells and consistently their rate of proliferation was very similar (see for example Figure 1b ). Both populations of cells expressed levels of the cell surface markers CD19, CD20 and CD23 that are characteristic of activated Bblasts (data not shown) and the EBV-infected cells expressed the latency III-associated proteins (Figure 1c) . It was noted that significantly higher levels of EBNA3B and EBNALP were expressed in the newly infected cells compared to the established LCL. The latter observation is consistent with earlier reports that large amounts of EBNALP are expressed early after infection (reviewed in Bornkamm and Hammerschmidt, 2001) .
EBV has no effect on p53 activation but blocks p21
WAF1/CIP1 accumulation after the exposure of B cells to cisplatin A series of experiments was performed to determine the response of these isogenic populations of recently isolated B cells to the genotoxic drug cisplatin. While the response of p53 appeared to be identical in both, it was discovered that p21 WAF1/CIP1 protein only accumulated in the mitogen-treated cells. In the EBV-infected cells -and several established LCLs -the level of p21 WAF1/ClP1 failed to increase (Figures 1d, 1e , 2a and 8a and our unpublished data). In every example of normal B cells latently infected with EBV and all LCLs analysed, no significant increase in p21 WAF1/CIP1 was detected. This was irrespective of which anti-p21
antibody was used. In most cases, after 12-16 h of exposure to cisplatin, p21 WAF1/CIP1 levels are actually reduced in the EBV-infected cells. This may be the result of cleavage by caspases activated in apoptotic cells (see below). p53 appeared to be activated and functional in the EBV-driven populations, since increases in Mdm2 protein and in p21 WAF1/CIP1 mRNA were consistently recorded. Figure 2 shows an example of a newly established LCL (o3 months in culture) in which p53 is stabilized, the amount of Mdm2 protein increased within 8 h; however, although there is a sixfold increase in p21 WAF1/CIP1 mRNA, newly synthesized p21
protein fails to accumulate. Several similar experiments were performed using this and another newly established LCL. Other RNAase protection assays (and also Northern blots) gave the same results (data not shown) and all were consistent with our previous data from other LCLs, showing that cisplatin induces an increase of p21 WAF1/CIP1 mRNA in these cells (Allday et al., 1995a) . Further analysis of cell cycle-associated proteins in the normal B cells cultured with CD40L/IL4 revealed that consistently the amount of cyclin D2 (but not cyclins D3, E or A or any CDK monitored) was significantly reduced 8-16 h after treatment with cisplatin ( Figure 3 ). In contrast, there was only a slight decrease in the level of cyclin D2 when EBV was present in either newly infected cells or in established LCLs (Figure 3 and our unpublished data). This reduction in the mitogen-treated cells could not WAF1/CIP1 fails to accumulate in EBV-infected cells after cisplatin-induced DNA damage. Primary B cells from two separate batches of buffy coats ((1) and (2)) were stimulated with CD40L/IL4 or EBV for 10 days, then were treated with 10 mg/ml cisplatin (Cp) and protein extracts were prepared at the indicated times after treatment. The levels of p53 and p21 WAF1/CIP1 in both populations were analysed by Western blotting using the appropriate MAbs. Bcl-2 or a nonspecific, cross-reactive band is shown as loading controls. p21 WAF1/CIP1 accumulated in the genotoxin-treated B cells stimulated with mitogen, but not in those infected with EBV. (e) A similar experiment to that shown in (d) was performed on a newly established LCL (CH-LCL). The extracts were split and run on two SDS-PAGE gels and Western blotted using two different anti-p21 WAF1/CIP1 -specific antibodies. Both produced the same result as the newly infected cells, that is, p21 WAF1/CIP1 did not accumulate in response to cisplatin. The slight decrease in p21 WAF1/CIP1 in the EBV-infected cells that sometimes occurs after 16 h corresponds to the appearance of apoptotic cells and probably represents proteolytic cleavage of p21 WAF1/CIP1 by activated caspases be accounted for by a downregulation of transcription since mRNA levels were similar in both the EBV-negative and -positive populations over the time course (data not shown). It was noted that the level of CDC25A, the phosphatase that removes inactivating phosphate groups from CDK2, decreased at a similar rate in both EBVnegative and -positive populations (Figure 4 ). This is consistent with the appearance of phosphorylated Chk2 kinase (which phosphorylates and targets CDC25A for degradation) in both populations and reports of various cell lines showing a similar response (Bartek and Lukas, 2001 ). This response suggests that cisplatin-induced damage and some elements of signalling are similar in both EBV-negative and -positive populations.
CDK2 remains active, hyperphosphorylation of pRB is maintained and replication of DNA can occur in DNA-damaged, EBV-infected B cells
In order to determine whether -in the mitogen-treated cells -p21 WAF1/CIP1 accumulated in CDK2-containing complexes after cisplatin treatment, coimmunoprecipitation WAF1/CIP1 to accumulate in EBVinfected cells does not result from reduced transcription. RPA analysis of p21 WAF1/CIP1 mRNA was performed using 10 mg total RNA extracted from the same LCL as used in a at 2 hourly intervals after cisplatin treatment.
32
P signals from protected fragments were quantified using a Storm 860 phosphorimager and values were normalized against those for the housekeeping gene GAPDH and plotted as fold-induction with the arbitrary value of 1 given to the level of expression at time point zero Figure 3 Effect of cisplatin-induced DNA damage on cell cycle regulators in mitogenically stimulated and EBV-infected normal B cells. The levels of the CDKs and those cyclins involved in G1 and S in B cells were analysed by SDS-PAGE and Western blotting of 30 mg protein extracts taken at the indicated times after addition of 10 mg/ml cisplatin (Cp) Figure 4 Effect of cisplatin-induced DNA damage on Chk2 and CDC25A. The levels of activated, phosphorylated Chk2 (p-Chk2) and the CDK2-activating phosphatase CDC25A were analysed by SDS-PAGE and Western blotting of 30 mg protein extracts taken at the indicated times after addition of 10 mg/ml cisplatin (Cp) Figure 5 (a) CDK2 bound p21 WAF1/CIP1 increases in CD40L/IL4-stimulated but not in EBV-infected normal B cells after treatment with cisplatin. Immunoprecipitations (IPs) were performed using a-CDK2 and a-CDK6 polyclonal rabbit antibodies (PAbs) on 300 mg of precleared extract prepared from EBV-infected LCL or mitogenically stimulated B cells treated with 10 mg/ml cisplatin (Cp) and harvested at the times indicated. Bound complexes were resolved by SDS-PAGE and the presence of p21 WAF1/CIP1 was shown by Western blotting using the PAb N-20. Control immunoprecipitations were carried out using a rabbit anti-CtBP serum. The immunoglobulin light chain that migrates just below 30 kDa is indicated ( * ). From each time point, 20% of the input extracts were Western blotted with anti-p21 WAF1/CIP1 PAb N-20 as indicated. (b) CDK2 remains active in EBV-infected B cells after treatment with cisplatin. Extracts were prepared from CD40L/IL4-stimulated or EBV-infected B cells at the times indicated after adding cisplatin (10 mg/ml). CDK2 complexes (lanes 2-4 and 6-8) were immunoprecipitated as described in (a) and their activity analysed by incubation with Histone H1 and [a-32 P] ATP. Samples from control immunoprecipitations using the anti-CtBP serum were run in lanes 1 and 5. The proteins were resolved by SDS-PAGE and visualized by autoradiography. The levels of phosphorylated Histone-H1 were quantified using the Storm 860 phosphorimager and shown as a histogram. (c) pRb is maintained in a hyperphosphorylated state in EBV-infected cells. Western blot analyses using a pan-specific anti-pRb Mab and a phospho-specific anti-pRb antibody (Ser807/811) were performed on cisplatin-treated extracts from EBV-and CD40L/IL4-stimulated normal B cells. Hyperphosphorylated pRb is still present in the EBV-infected cells after exposure to cisplatin for 16 h. A nonspecific, cross-reactive band is shown to demonstrate equal loading. (d) EBV-driven normal B cells continue to synthesize DNA after exposure to cisplatin. B cells stimulated with CD40L/IL4 or EBV for 10 days were treated with 10 mg/ml cisplatin for 4 h and then transferred to drug-free medium. At 20 h after exposure to cisplatin, treated and untreated cells were pulsed with 10 mm BrdU for 1 h, stained for BrdU incorporation and DNA content prior to analysis by flow cytometry. The cells with a sub-G1 DNA content were electronically gated-out so that the live 2N-4N cells are shown clearly. (e) EBV-infected cells undergo apoptosis following DNA damage induced by cisplatin. B cells stimulated with CD40L/IL4 or EBV were treated as in (d) but were stained with propidum iodide (PI) alone. To show clearly the distribution of cells in all compartments, particularly sub-G1, cells with a 2N DNA content were set at 400 and those with a 4N content were set at 800 on the FL2-axis. (f) Proteolytic cleavage of the caspase substrate PARP was investigated by Western blotting extracts taken from the treated and untreated cells. Cleavage of PARP in the EBV-infected cells corresponds to the apoptosis seen as having a o2N DNA content in (e) experiments were performed. Western blotting (with anti-p21
antibodies) of CDK2 and CDK6 immunoprecipitations confirmed that, in the mitogenically activated cells, the p21 WAF1/CIP1 induced by cisplatin was associated with CDK2-containing complexes and was lost from CDK6 complexes. In contrast, no increase in p21 WAF1/CIP1 in the input protein extract or CDK2/p21 WAF1/CIP1 complexes was detected in the extracts from the EBV-infected cells after similar treatment (Figure 5a ).
Consistent with CDK2 remaining active in the EBVdriven cells that were treated with cisplatin, CDK2 kinase activity was maintained ( Figure 5b ) and pRb remained hyperphosphorylated. In contrast, in the mitogen-treated cells, CDK2 activity declined and concomitantly hyperphosphorylation of pRb was reduced ( Figure 5c ). EBV-driven cells exposed to cisplatin were still capable of entering S phase and incorporating BrdU (Figure 5d , lower right panel). In contrast, mitogen-stimulated cells treated in the same manner failed to incorporate BrdU or enter S phase. The distribution of these cells in all phases of the cell cycle suggests that they arrested largely in G1 but also in S phase and G2/M (Figure 5d , lower left panel). The observations that nearly 30% of the propidium iodidestained, EBV-positive cells were distributed in the sub-G1 compartment and that there was proteolytic cleavage of the caspase substrate poly(ADP-ribose) polymerase (PARP) after exposure to cisplatin for 4 h (Figure 5e and f) are consistent with our previous reports that cisplatin can induce p53-mediated apoptosis in LCL cells (Allday et al., 1995a, b) . Apoptosis in LCL cells in which p21
WAF1/CIP1 fails to accumulate following genotoxic stress is also consistent with various reports that the absence of functional p21 WAF1/CIP1 predisposes cells to programmed cell death after sustained DNA damage (Polyak et al., 1996; Waldman et al., 1996; Chattopadhyay et al., 2001 ).
Cleavage of p21
WAF1/CIP1 by caspases does not mask p21
WAF1/CIP1 accumulation after treatment of EBV-infected cells with cisplatin
The EBV-infected B cells -whether newly infected or established LCLs -continue to synthesize DNA but can also undergo apoptosis in response to cisplatin. Since p21 WAF1/CIP1 can be cleaved by caspases activated in this process (Zhang et al., 1999) , we wanted to be sure that the failure of p21 WAF1/CIP1 to accumulate in these cells was not because it was targeted by caspases after exposure of the cells to cisplatin. Experiments were performed using the pan-specific caspase inhibitor ZVAD. An example is shown in Figure 6 . After exposure of the cells to cisplatin for 12 h, p21 WAF1/CIP1 does not increase (as can also be seen in Figures 1, 2 and 8) . If ZVAD was also added, although it inhibits the cleavage of PARP and blocks apoptosis, it does not produce an increase in p21
. This indicates that proteolytic cleavage during apoptosis does not mask the accumulation of p21 WAF1/CIP1 in the EBV-infected cells.
Inhibition of the proteasome reveals that p21 WAF1/CIP1 is translated
Since p21
WAF1/CIP1 protein accumulation was divorced from transcription of the p21 WAF1/CIP1 gene in the EBV-positive B cells after exposure to cisplatin, we asked whether newly synthesized p21 WAF1/CIP1 was being translated but rapidly degraded by the proteasome system. In order to determine whether the failure of p21 WAF1/CIP1 to accumulate is proteasome-dependent, a newly established LCL (also used for the experiments shown in Figures 2 and 8 ) was treated with cisplatin and simultaneously the proteasome inhibitor MG132 (cbz-LLL) was added at increasing concentrations. Samples were taken after 4 h and analysed by Western blotting. In the extracts from cells left untreated or treated with 0.01 mm MG132, cisplatin induced a detectable increase in p53 but no accumulation of p21 WAF1/CIP1 (Figure 7 , compare lanes 1-4). However, in the sample from cells treated with 0.1 mm MG132, inhibiting proteasome activity revealed a significant increase in the amount of p21 WAF1/CIF1 after exposure to cisplatin for 4 h (Figure 7 , compare lanes 5 and 6). This means that in the presence of cisplatin, de novo synthesis of p21 WAF1/CIP1 probably occurs in EBV-infected cells. Higher concentrations of MG132 had the effect of stabilizing both p53 and p21 WAF1/CIP1 even in the absence of cisplatin (Figure 7 , lanes 7 and 8 and data not shown). In all these experiments, the level of Bcl-2 was unaltered and in accumulation after cisplatin-induced damage in LCL cells. Caspase-mediated proteolytic activity was inhibited in a newly established LCL (CH-LCL) by the addition of 50 mm zVAD-fmk for 1 h prior to treatment with 10 mg/ml cisplatin. Protein was extracted from untreated cells and cells treated with cisplatin in the presence or absence of caspase inhibitor 12 h after the addition of the genotoxin. The levels of p21 WAF1/CIP1 , PARP and Cdc2 were analysed by probing Western blots with the appropriate antibodies. Inhibition of PARP cleavage shows caspase activity and Cdc2 (which is unaffected by caspases) is shown as a loading control Figure 7 Inhibition of proteosome-mediated proteolysis reveals an increase in p21 WAF1/CIP1 following the treatment in EBV-infected B cells with cisplatin. A newly established LCL (ED-LCL) was treated with 0.01 (lanes 3 and 4), 0.1 (lanes 5 and 6) or 0.2 mm (lanes 7 and 8) of the proteosome inhibitor MG132 (cbz-LLL) in the presence or absence of 10 mg/ml cisplatin (Cp). Lanes 1 and 2 show the extracts from untreated and cisplatin-only treated cells. Samples were harvested 4 h after the addition of inhibitor and cisplatin. The levels of p53 and p21 WAF1/CIP1 were shown by Western blotting with the appropriate MAbs. The level of Bcl-2 remains unchanged in the presence of both cisplatin and proteosome inhibitor and hence is included as a control to show equal loading. Autoradiographs exposed for a relatively short period are shown
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Figure 8 DNA-damage from g-irradiation induces cell cycle arrest and the accumulation of p21 WAF1/CIP1 in EBV-driven and mitogenically stimulated normal B cells. Newly established ED-LCL and CD40L/IL4-stimulated B cells were exposed to 8.5 Gy (850 rad) of g-irradiation (g) and cells from treated and untreated populations were taken at the indicated times after exposure. (a) In the two panels on the left, 30 mg of protein extract taken was resolved by SDS-PAGE and analysed by Western blotting for p53 and p21 WAF1/CIP1 . A nonspecific band is shown as a loading control. The right-hand panel shows, for comparison, extracts from the same LCL (ED-LCL) treated with cisplatin and analysed in a similar way. Here Bcl-2 shows equal loading. (b) The cell cycle profiles were analysed by flow cytometry 24 h after exposure to 8.5 Gy g-irradiation or left untreated. (c) In order to confirm that ED-LCL arrests in G1 and G2 of the cell cycle, cells were pulsed with BrdU for 1 h and transferred to label-free medium prior to exposure to 8.5 Gy girradiation. The progression of labelled cells after irradiation was analysed after 24 h by dual parameter flow cytometry of samples costained for BrdU and DNA. Cells in G1 (with a 2N DNA content) were set at 200 on the FL2-A axis and those in G2 (with a 4N DNA content) were set at 400. Cells arrested after 24 h are indicated with arrows EBV can inhibit G1 arrest J O'Nions and MJ Allday cells from the same LCL treated only with cisplatin, although p53 was stabilized, as anticipated the level of p21 WAF1/CIP1 remained pretty stable for at least 12 h after treatment (see the cisplatin experiment, Figure 8a ). Collectively, these results indicate that in B cells infected with EBV and expressing the latency III programme, activated p53 can induce the synthesis of p21 WAF1/CIP1 mRNA and this is translated to produce p21
protein, but that the latter is very rapidly degraded by the proteasome system. However, formally we cannot rule out the possibility that cisplatin induces an increase in proteasome-mediated degradation of p21
when latent EBV is present. Whatever the precise mechanism, the net result is that the steady-state level of p21 WAF1/CIP1 does not increase and therefore CDK2 activity is not suppressed.
g-Irradiation induces cell cycle arrest and the induction of p21
WAF1/CIP1 by a mechanism that is not inhibited by EBV It has been reported that g-irradiation can induce cell cycle arrest in EBV-immortalized B cells (i.e. LCLs); in two LCLs studied, cell cycle arrest correlated with an increase in p21 WAF1/CIP1 synthesis and inhibition of CDK2 activity (Cannell et al., 1998) . The difference between these responses and the responses to cisplatin we have shown here clearly required consideration. In order to determine whether the differences are a consequence of the cell lines used, similar experiments were performed using the LCLs we have studied here. The results, summarized in Figure 8 (and unpublished data), consistently showed that the response of newly established LCLs (and also mitogenically activated B cells) to g-irradiation was indistinguishable from the data reported by Cannell and colleagues. The same LCLs that respond to cisplatin with a suppression of p21 WAF1/CIP1 accumulation and inhibition of G1 arrest responded to 8.5 Gy of g-irradiation by arresting in both G1 and G2 of the cell cycle. The arrest was accompanied by an increase in p53 and an increase in p21
protein. As expected, since the cells arrested but did not undergo apoptosis, no cleavage of PARP was detected in the g-irradiated cells (data not shown). Surprisingly, no change was seen in the level of cyclin D2 after g-irradiation of either the mitogen-or EBV-driven cells (data not shown). It was also noted that the kinetics and magnitude of p53 stabilization were very similar, irrespective of the genotoxin used. These experiments clearly demonstrate that cisplatin and g-irradiation trigger different signals in LCL cells and latency functions of EBV must discriminate between these.
Discussion
Previously, it has been proposed that EBV differs fundamentally from SV40 virus, the papillomaviruses and adenoviruses in that, although it is a tumour virus, EBV drives cell proliferation by stimulating B cell activation and growth programmes rather than by subverting cell cycle regulatory mechanisms (Cannell et al., 1996; Bornkamm and Hammerschmidt, 2001; Rickinson, 2001 ). However, here we have revealed, by using cisplatin to trigger checkpoints, that although latent EBV does not appear to affect the activity of p53, it can act downstream of this tumour suppressor and interfere with the regulation of the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 and cyclin-dependent kinase CDK2. By preventing the accumulation of newly synthesized p21 WAF1/CIP1 in actively proliferating cells exposed to cisplatin, EBV appears to prevent the inactivation of CDK2, and therefore replication of damaged DNA is not inhibited. In addition, EBV appears to inhibit the degradation of cyclin D2 in these genotoxically stressed B cells. Since cyclin D1 is not expressed in LCLs or in activated B-blasts (Palmero et al., 1993 and our unpublished data), we assume that cyclin D2 is playing a similar role to that played by cyclin D1 in epithelial cells (Agami and Bernards, 2002) . When cyclin D2 is degraded, it presumably frees p21 WAF1/CIP1 from cyclin D/CDK4 (or 6) complexes to bind and inactivate cyclin E/CDK2. By preventing the reduction in cyclin D2, EBV will reduce the amount of p21 WAP1/CIP1 that can redistribute into cyclin E/CDK2 complexes and inactivate them. Currently, the mechanism by which cyclin D2 is downregulated in the normal B-blasts is unknown. In LCL and newly infected B cells, it may be significant that the EBV latent proteins EBNA2 and EBNALP cooperate to stimulate cyclin D2 synthesis (Sinclair et al., 1994; Spender et al., 2001) ; however, this regulation seems to be primarily at the level of transcription.
How does latent EBV prevent the accumulation of p21
WAF1/CIP1
? Since there is increased transcription producing p21 WAF1/CIP1 mRNA, it is possible that there is a block to its translation in the presence of EBV latency III gene expression. However, the demonstration that in the presence of the proteasome inhibitor MG132, cisplatin can induce an increase in p21 WAF1/CIP1 protein provides compelling evidence that p21 WAF1/CIP1 mRNA is indeed translated in the presence of EBV. Immediately thereafter, EBV must direct the degradation of this newly synthesized protein. How does EBV target p21 WAF1/CIP1 for degradation? Obtaining a precise answer to this question is likely to be a lengthy process. Currently, it is far from clear how the turnover of p21 WAF1/CIP1 is regulated in normal cells or what signals are involved. Also, since the EBV-associated phenotype could require one or more of nine latent EBV proteins or several RNA species, at this stage we can only speculate. p21 WAF1/CIP1 belongs to the CIP/KIP family of CDK inhibitors and is a key negative regulator of cell cycle progression, particularly through its interaction with cyclin E/ and A/CDK2-containing complexes. However, since p21 WAF1/CIP1 also acts positively in the assembly and activation of cyclin D/CDK4 and 6 complexes, its expression must be very finely regulated, both transcriptionally (by p53) and post-translationally (by the proteasome system) (Sherr and Roberts, 1999 (Sheaff et al., 2000; Touitou et al., 2001) . Physical studies have shown that when p21 WAF1/CIP1 is not part of a functional protein complex, it is very loosely folded, so much so that it has been described as 'natively disordered' (Kriwacki et al., 1996; Lui et al., 2003) . Since this relatively unstructured protein can directly contact the 20S proteasome through an interaction with the C8 (a7) subunit and it is degraded by purified 20S proteasomes, we have suggested that free, uncomplexed p21
may be eliminated by a default mechanism for destroying unfolded or misfolded proteins (Touitou et al., 2001) . Recently, Lui and colleagues have suggested that natively disordered substrates such as p21 WAF1/CIP1 might possess features that promote the activation or 'gating' of the latent 20S proteasome without the need for polyubiquitin modification or regulatory structures such as the 19S proteasome (Lui et al., 2003) . If this model is correct, then a major determinant of p21
stability in cells will be the availability of proteins with which p21
WAF1/CIP1 can form functional complexes. In particular, the C-terminus of p21 WAF1/CIP1 is the site of numerous interactions with other cellular proteins (including PCNA, cyclin/CDKs and C8) and is also the location of multiple targets for cellular kinases. This region is therefore likely to play a major role in the regulation of p21 WAF1/CIP1 turnover (Dotto, 2000; Scott et al., 2002) . Since in the EBV-negative B cells treated with cisplatin, most of the newly synthesized p21
WAF1/CIP1 appears to form complexes with CDK2 (Figure 5a ), EBV could be acting on either p21 WAF1/CIP1 or CDK2 in a fashion that prevents p21 WAF1/CIP1 from forming such complexes and so exposing it as an unfolded substrate for the proteasome. Alternatively, EBV may increase the access to or affinity of p21 WAF1/CIP1 for proteasomes. Presently, we have no insight into the mechanism of accelerated degradation or identity of the EBV gene product(s) responsible for this phenotype. However, identifying the individual latent gene or genes should provide important clues to the signals and interactions involved.
The experiments in which g-irradiation was the agent inducing DNA damage confirmed that LCL cells respond to this treatment by arresting both in G1 and G2 of the cell cycle (see Figure 8c ). This correlated with an accumulation of p21 WAF1/CIP1 and inactivation of CDK2 (Cannell et al., 1998) and is largely indistinguishable from the response of the mitogenically activated B cells exposed to 8.5 Gy. Although the EBV-infected cells sometimes have a slightly higher basal level of p21
, these experiments show that newly synthesized p21
WAF1/CIP1 can accumulate in LCL cells exposed to at least one form of genotoxic stress. However, the intriguing conclusion we can draw from these results is that the type of damage that is generated by a genotoxin determines whether or not the response is modified by the presence of latent EBV. Cisplatin, which generates DNA adducts, intra-and interstrand crosslinks, provokes a modification of the G1 arrest downstream of p53; in contrast, g-irradiation causes double-strand breaks in DNA and activates no obvious EBV-dependent modification of the response. At this stage, we cannot exclude the possibility that some type of damage -or signalling pathway associated with it -modifies an EBV protein function or vice versa. It appears that EBV has evolved subtle mechanisms that discriminate between signalling pathways activated by different types of DNA damage. These mechanisms perhaps play important roles in the complex life cycle of this persistent human tumour virus. The deregulation of the p53-pRb axis downstream of p53 and upstream of pRb is also likely to contribute to the 'immortalization' phenotype in B cells in vitro.
The links between cell cycle checkpoint failure, genome destabilization and cancer are very well established (Hartwell and Kastan, 1994; Paulovich et al., 1997; Hoeijmakers, 2001) and it has been shown that the deregulation of p21 WAF1/CIP1 or cyclin E (and hence the G1 checkpoint) induces genomic instability (Waldman et al., 1996 : Spruck et al., 1999 . Here, we have shown that EBV can target p21
WAF1/CIP1 by a novel mechanism; therefore, it is reasonable to assume that sustained expression of the EBV proliferation programme -as may occur in an immunosuppressed individual -could lead to the destabilization of the B cell genome. It is becoming clear that the LCL-like B-blasts -produced when EBV infects naı¨ve or memory B cells in vivo -are probably the precursors of not only PTLD but also Burkitt's lymphoma and the Reed-Sternberg cells of Hodgkin's disease (Thorley-Lawson and Babcock, 1999; Thorley-Lawson, 2001; Kelly et al., 2002; Speck, 2002; Timms et al., 2003) . EBV could therefore be contributing to the development of all these various neoplasias by increasing the likelihood of cells replicating oncogenic mutations or becoming aneuploid. Indeed, there is considerable evidence that multiple genetic and epigenetic changes are necessary for the development of this spectrum of B cell tumours (Knowles et al., 1995; Kelly et al., 2002; Lindstrom and Wiman, 2002; Timms et al., 2003) . Finally, since cells with insufficient p21 WAF1/ClP1 to exert an antiproliferative effect are highly prone to apoptosis when their genome is severely damaged (Polyak et al., 1996; Chattopadhyay et al., 2001) , the data presented here suggest that EBV-driven tumour cells may be more likely to undergo apoptosis than normal B cells in response to at least some anticancer drugs.
Materials and methods

Cell isolation and culture
Primary B cells were isolated from a mixture of plateletdepleted buffy coat residues from multiple blood donors (North London Transfusion Service) by positive selection as described previously (Cannell et al., 1996; Spender et al., 1999) . Briefly, buffy coats were centrifuged over Ficoll-Paque-Plus TM gradients (Amersham Biosciences) and CD19-positive B cells were immunoselected from the mononuclear layer by incubation with M450 pan B Dynabeads (anti-CD19 monoclonal antibody-coated magnetic beads (Dynal)). Other cell types were removed by repeated washing and the beads were released by competition with Detachabeads (Dynal). The isolated B cells were resuspended in 15% (v/v) FCS/RPMI-1640 (Gibco Invitrogen) at a density of 10 6 /ml. Purity of the isolated B cells was confirmed by flow cytometry using fluorescein isothiocyanate (FITC)-conjugated anti-CD20 monoclonal antibody (DAKO).
Purified B cells were cultured and incubated for 36 h after isolation prior to infection with EBV or stimulation with CD40L/IL4. They were then passaged in 10% (v/v) FCS/ RPMI-1640 at 371C.
Infection with EBV and stimulation with CD40L and IL4
EBV was purified by ultrafiltration from B95.8 cells and used to infect primary B cells as previously described (Spender et al., 1999) . Briefly, the purified B cells were incubated with B95.8 EBV at a density of 10 7 /ml for 2 h at 371C. Cells were then diluted to 10 6 /ml in their own conditioned medium to stop the infection (Wade and Allday, 2000) .
Purified resting B cells that were to be stimulated through CD40 were seeded in 75 cm 2 flasks at 10 7 cells per flask on a feeder layer of 1.5 Â 10 6 CD40L-L cells that had been gamma (g)-irradiated with 50 Gy (Garrone et al., 1995) . The RPMI growth medium was then supplemented with 10 U/ml human recombinant IL4 (R&D).
Genotoxic agents, caspase and proteasome inhibitors
In order to induce DNA damage, cells were treated with cisplatin (Faulding Pharmaceuticals Plc) at a final concentration of 10 mg/ml or were exposed to 850 rad (8.5 Gy) of g-irradiation using a 137 Cs source. The pan-caspase inhibitor ZVAD-fmk (caspase inhibitor 1, Calbiochem) was used at a final concentration of 50 mm. The proteosome inhibitor MG132 (cbz-LLL) (SIGMA Aldrich) was resuspended in dimethyl sulphoxide (DMSO) to make a stock solution of 10 mm and added to cells at a range of final concentrations from 0.01 to 1 mm to inhibit proteosome-mediated proteolytic activity.
Flow cytometry and BrdU labelling
All flow cytometry was performed using a Beckton-Dickinson FACSort flow cytometer and analysed with CellQuest software. Proliferating cells or cells treated with cisplatin were harvested at the times indicated and fixed in 80% ethanol. To analyse the cell cycle distribution, fixed cells were resuspended in PI solution (PBS containing 18 mg/ml propidium iodide (PI) and 8 mg/ml RNase A (both Sigma Aldrich)) and incubated at 41C for 1 h as previously described (Parker et al., 2000; Wade and Allday, 2000) .
To analyse the proportion of cells entering and passing through S phase, B cells were incubated with 10 mm 5-bromo-2 0 -deoxyuridine (BrdU) (Sigma Aldrich) added to the growth medium for 1 h at 371C. The cells were pelleted by centrifugation, washed in prewarmed PBS and resuspended in label-free medium. After fixation, the cells were permeabilized with Triton X-100, their DNA denatured and stained with FITCconjugated anti-BrdU monoclonal antibody (Becton Dickinson) as described previously (Wade and Allday, 2000) . The cells were washed in 0.5% Tween-20-PBS and resuspended in PI solution as above. Cells were passed repeatedly through a 25-gauge needle prior to analysis by flow cytometry and any remaining doublets were excluded from the analysis by electronic gating.
SDS-PAGE and Western blotting
Protein extraction using RIPA (radioimmunoprecipitation) lysis buffer, quantification of protein and Western blotting were all performed as described previously (Wade and . A measure of 30 mg of protein extract was fractionated in 12, 10 or 7.5% sodium dodecyl sulphate (SDS)-polyacrylamide gels using a mini-PROTEAN II cell (BioRad) and transferred onto Protran nitrocellulose membrane. Membranes were probed with the following antibodies: monoclonal antibodies (MAbs) to p21 WAF1/CIP1 (Sx118), p53 (DO-1) and MDM2 (SMP14, 482, 2A10) were kind gifts from Xin Lu; MAb to Rb (10014) and MAb to cyclin D2 (G132-43) (PharMingen); polyclonal antibodies (PAbs) to CDK2 (M2), CDK4 (C-22), CDK6 (C-21) and cyclin D3 (C-16) and MAbs to cyclins A (BF683) and E (HE12) and CDC25A (F-6) (Santa Cruz); PAb to CDK1 (Ab-1) (Oncogene), MAb to Bcl-2 (DAKO); PAb to PARP (Roche/Boehringer Mannheim), PAb to phospho-Chk2 (Thr68) and PAb to phospho-Rb (Ser807/811) (Cell Signalling Technologies); MAb to EBNA3C (A-10, a gift from Martin Rowe); PAbs to EBNA3A and EBNA3B (Exalpha); MAb to EBNA-LP (JF158); MAbs to LMP1 (CS1-4) and EBNA2 (PE2, DAKO) and a human serum that recognizes EBNA 1. Each antibody was used in accordance with the supplier's instructions.
The secondary antibodies used were horseradish peroxidase (HRP)-conjugated goat anti-rabbit Ig (DAKO) for rabbit polyclonal primary Abs or unconjugated rabbit anti-mouse Ig (DAKO) followed by goat anti-rabbit-HRP for mouse monoclonal primary Abs. Bound proteins were visualized by enhanced chemiluminescence (Amersham Biosciences).
RNase protection assay (RPA)
Cellular RNA was extracted using RNA Bee (Biogenesis) and 10 mg of total RNA was used per RPA. The multiprobe template hCC-2 human cell cycle set (Pharmingen) was used to generate 32 P-labelled transcripts to analyse the expression of p21
WAF1/CIP1
. RPA was performed as described previously (Spender et al., 2001 ) using the RPA III RNase protection assay kit (Ambion). Quantification was performed using a Storm 860 phosphorimager (Molecular Dynamics).
Immunoprecipitations and kinase assay
Extracts were prepared by lysing cells at 41C with rotation in 1% (v/v) NP40, 50 mm Tris pH 8, 150 mm NaCl, 1 mm EDTA, 10 mm b-glycerophosphate, 1 mm DTT, 10 mm NaF, 2 mm Na 3 VO 4 , 1 mm PMSF and 2 mm complete protease inhibitor cocktail (Roche). After centrifugation at 14 000 r.p.m. in a microfuge (Eppendorf) to remove any cell debris, the lysates were precleared by incubation with protein-G sepharose beads. In all, 300 mg of cleared lysates was then incubated with 4 mg of either rabbit PAb to cdk2 or cdk6 or 2 mg rabbit PAb to CtBP (matched control) at 41C for 4 h and the immunocomplexes were collected by incubation with protein G-sepharose for a further 3 h before centrifugation (14 000 r.p.m. in an Eppendorf microfuge). The complexes were washed four times in NP40 lysis buffer before boiling in 2xSDS-buffer, separated on a 12% SDS-polyacrylamide gel and transferred to nitrocellulose. The membrane was blocked and probed for the presence of p21 WAF1/CIP1 with the polyclonal Ab N-20 (Santa Cruz). In order to assay for CDK2 activity, complexes were immunoprecipitated from B cell extracts as described above. The bead-bound complexes were washed twice more in kinase buffer (50 mm Tris, 10 mm MgCl 2 ) before incubation in 50 ml kinase buffer (including 1 mm DTT, 10 mm ATP, 0.5 mg/ml Histone H1 and 10 mCi/ml 32 Pa-ATP) at 301C for 30 min. The reaction was stopped by adding 2xSDS sample buffer, the samples were boiled and resolved on an SDS-polyacrylamide gel. The signals were visualized by autoradiography and quantified using the Storm 860 phosphorimager (Molecular Dynamics).
